News from grifols A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Jun 08, 2022, 05:00 ET Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening

Jun 08, 2022, 05:00 ET Grifols Procleix Plasmodium Assay erhält als erster CE-Kennzeichnung fürMalaria-Blut-Screening

Jun 08, 2022, 05:00 ET Procleix Plasmodium Assay di Grifols riceve il marchio CE, il primo test per il rilevamento del parassita della malaria nel sangue

Jun 08, 2022, 05:00 ET Le test Procleix Plasmodium de Grifols reçoit le marquage CE, une première pour un test de dépistage sanguin du paludisme

Apr 29, 2022, 14:00 ET Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022

Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United...

Mar 10, 2022, 05:00 ET XEMBIFY® de Grifols reçoit des approbations européennes, élargissant l'accès à des thérapies innovantes pour les patients

Mar 02, 2022, 09:00 ET Grifols partners with Feeding America® to help address hunger in the U.S.

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the...

Feb 24, 2022, 06:00 ET Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced a collaboration...

Jan 04, 2022, 12:30 ET Grifols acquires its first plasma donation center in Canada

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today...

Oct 19, 2021, 11:18 ET Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record...

Jul 19, 2021, 06:00 ET Grifols étend son activité en Afrique en signant un accord pour la création d'une usine de fabrication de solutions intraveineuses au Nigeria

Jul 19, 2021, 06:00 ET Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria

- To be constructed by Grifols Engineering, a global standard-bearer in the development and building of advanced production facilities for the...

Jun 01, 2021, 10:30 ET Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure...

Apr 15, 2021, 09:00 ET Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100...

Apr 09, 2021, 10:30 ET Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United ...

Mar 25, 2021, 06:00 ET Les tests Procleix UltrioPlex E et Procleix Babesia de Grifols reçoivent le marquage CE

Mar 25, 2021, 06:00 ET Grifols Procleix UltrioPlex E and Procleix Babesia assays receive CE mark

Mar 25, 2021, 06:00 ET Grifols Procleix UltrioPlex E und Procleix Babesia Assays erhalten CE-Kennzeichnung

Mar 25, 2021, 06:00 ET I test Procleix UltrioPlex E e Procleix Babesia di Grifols hanno ottenuto il marchio CE

Mar 22, 2021, 09:00 ET Grifols installs first-ever DG Reader Net analyzer in North America

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of...

Mar 18, 2021, 06:00 ET Grifols launches patient point-of-care system for monitoring infliximab in Europe

Mar 18, 2021, 06:00 ET Grifols lance le système de points de service pour les patients en vue du suivi de l'infliximab en Europe

Mar 18, 2021, 06:00 ET Grifols lancia in Europa un sistema point-of-care per il monitoraggio terapeutico di infliximab

Feb 23, 2021, 09:00 ET Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for...